Key Highlights
• BioMarin announced five-year Phase 3 data for Pombiliti and Opfolda in adults with late-onset Pompe disease on Friday.
• Adults maintained walking distance over five years of continuous therapy, while respiratory function stayed relatively stable.
• No new safety signals were identified, and the analysis followed 82 patients with differing treatment histories.
• BioMarin acquired Amicus Therapeutics in December, which had marketed the combination therapy, expanding its rare metabolic disease presence.
Five Years of Follow-Up
BioMarin Pharmaceutical (NASDAQ:BMRN) announced five-year data on Friday from a Phase 3 trial of Pombiliti and Opfolda, a combination therapy for late-onset Pompe disease, known as LOPD. The company reported that adults taking the combination maintained their walking distance across five years of continuous therapy.
Respiratory function remained relatively stable over the long term, and no new safety signals were identified in the data. The results were presented at the 31st annual Congress of the World Muscle Society in Japan.
Who Was in the Analysis
The five-year figures come from the Phase 3 trial of the two drugs given together. The analysis followed 82 patients. Some were new to enzyme replacement therapy, while others had received an enzyme replacement therapy before joining the study. Including both groups means the dataset covers adults who began the combination from different treatment histories.
Walking distance and respiratory function were the two outcomes the announcement emphasized, with safety findings reported alongside them. The trial period covered five years of uninterrupted treatment.
Reading the Results
Three findings stand out in the announcement. Walking distance was maintained, respiratory function remained relatively stable, and no new safety signals appeared. Each was assessed in adults with LOPD over five years of continuous therapy.
Because the 82 patients included both people new to enzyme replacement therapy and people previously treated with one, the results are reported across both starting points rather than for a single group.
What Late-Onset Pompe Disease Involves
LOPD is a rare, inherited lysosomal disorder that can be severe. It involves progressive muscle weakness throughout the body that worsens over time. In many patients, the muscles that control breathing are affected, which is why respiratory function is tracked alongside walking distance.
The condition worsens over time, and the new data cover five years of continuous treatment, with walking distance and respiratory function followed throughout.
A Portfolio Built Through Acquisition
BioMarin acquired Amicus Therapeutics in December. Amicus had marketed the Pombiliti and Opfolda combination, so the therapy and its trial data now sit within BioMarin's portfolio. The transaction expanded BioMarin's presence in the rare metabolic disease space, and the combination therapy now forms part of its rare disease offering.
BioMarin shares traded 1.32 percent lower on Friday, according to the quote shown with the announcement.






Please wait processing your request...